{"id":"W4387252273","doi":"10.1038/s41591-023-02589-w","title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University Health Network; University of Calgary; Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"National Cancer Institute; SkylineDx; Genentech; MEI Pharma; Jazz Pharmaceuticals; Teva Pharmaceutical Industries; Karyopharm Therapeutics; Gilead Sciences; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Multiple myeloma; Cytokine release syndrome; Gastroenterology; Refractory (planetary science); Clinical endpoint; Adverse effect; Cumulative incidence; Progression-free survival; Surgery; Oncology; Clinical trial; Chemotherapy; Cancer; Immunotherapy; Cohort","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001098136,0.0003069104,0.0006295063,0.0005765903,0.0001508923,0.00001233329,0.0002891204,0.0004419834,0.001312763],"category_scores_gemma":[0.006092535,0.0001492331,0.0001115377,0.001760495,0.0002842874,0.00006404908,0.00008623576,0.001854771,0.0002925895],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001841922,"about_ca_system_score_gemma":0.0002633624,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002287995,"about_ca_topic_score_gemma":0.0004223585,"domain_scores_codex":[0.996865,0.0002126284,0.0005246753,0.000515195,0.001184269,0.0006981811],"domain_scores_gemma":[0.9972963,0.001355062,0.0001047991,0.0007699443,0.0001314704,0.0003423685],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4510469,0.00309892,0.007377972,0.0003649316,0.0004971519,0.01830454,0.002072265,0.000003637585,0.01523997,0.0002259386,0.2111604,0.2906073],"study_design_scores_gemma":[0.7091025,0.01130929,0.08394355,0.0005901398,0.0002063056,0.0001852479,0.0009866558,0.002403472,0.001155515,0.0001331433,0.1896823,0.0003019035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9653992,0.003147211,0.000005558983,0.02389512,0.001145352,0.002744914,0.00004475445,0.0002459597,0.003371945],"genre_scores_gemma":[0.9862692,0.0006265287,0.0001008792,0.001206066,0.001350678,0.0002364719,0.0004227332,0.0000522245,0.00973525],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2903054,"threshold_uncertainty_score":0.9996002,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04272326740296717,"score_gpt":0.3915068327786259,"score_spread":0.3487835653756587,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}